Phosphate meeting cholesterol—consequences for cardiovascular disease in chronic kidney disease?
- 1 June 2021
- journal article
- editorial
- Published by Elsevier BV in Kidney International
- Vol. 99 (6), 1264-1267
- https://doi.org/10.1016/j.kint.2021.02.022
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Hyperphosphatemia in chronic kidney disease exacerbates atherosclerosis via a mannosidases-mediated complex-type conversion of SCAP N-glycansKidney International, 2021
- Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a differenceAtherosclerosis, 2015
- Inflammatory Stress Induces Statin Resistance by Disrupting 3-Hydroxy-3-Methylglutaryl-CoA Reductase Feedback RegulationArteriosclerosis, Thrombosis, and Vascular Biology, 2014
- Dietary phosphate restriction induces hepatic lipid accumulation through dysregulation of cholesterol metabolism in miceNutrition Research, 2013
- Phosphate: The new cholesterol? The role of the phosphate axis in non-uremic vascular diseaseAtherosclerosis, 2012
- Dietary Phosphate Modulates Atherogenesis and Insulin Resistance in Apolipoprotein E Knockout Mice—Brief ReportArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient miceNephrology Dialysis Transplantation, 2011
- Serum Phosphorus Levels Associate with Coronary Atherosclerosis in Young AdultsJournal of the American Society of Nephrology, 2009
- Sevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E–Deficient MiceJournal of the American College of Cardiology, 2005